Drugs / Langerhans-type dendritic cells
Langerhans-type dendritic cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01456104 | Oct 2011 → Jan 2023 | melanoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Langerhans-type dendritic cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01456104 ↗ |
| Known as | Langerhans cells | “Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)” NCT01456104 ↗ |
| Known as | LCs | “Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)” NCT01456104 ↗ |
| Route | Subcutaneous | “These cells then will be injected under the skin.” NCT01456104 ↗ |